Gorilla Research Insights logoGorilla Research InsightsRESEARCH GRADE
Research education

NAD+ 1000 mg: Separating Biochemical Importance From Clinical Evidence

NAD+ 1000 mg: Separating Biochemical Importance From Clinical Evidence — research illustration

CELLULAR METABOLISM NAD+ 1000 mg: Separating Biochemical Importance From Clinical Evidence NAD+ sits at the center of cellular redox metabolism, but a larger labeled vial mass does not establish greater target engagement, benefit, or safety. Those are empirical questions.

Biology versus intervention

Cells synthesize and recycle NAD+ through regulated pathways. Depletion models and precursor experiments have made the NAD system an active research field. In humans, randomized studies of nicotinamide riboside have demonstrated changes in the NAD metabolome, with inconsistent effects on downstream physiological endpoints [1][2]. Those results cannot be transferred directly to intact NAD+.

Evidence for intact NAD+

Direct human evidence is limited. A pilot infusion study characterized time-dependent plasma and urinary metabolites rather than therapeutic efficacy [3]. A recent retrospective clinic study described tolerability differences and exploratory biomarkers, but lacked random allocation and was not designed to prove broad clinical benefit [4]. No cited trial compares a 1000 mg research vial with 500 mg and establishes a superior outcome. Milligram strength should therefore be treated as inventory information, not a clinical recommendation.

What rigorous research would ask

Priority questions include whether intact NAD+ reaches relevant compartments, which metabolites mediate observed effects, how exposure scales, and whether prespecified outcomes improve in randomized controlled studies. Product identity and sterility are separate quality questions.

Primary sources

[1] Trammell et al. Nicotinamide riboside and the human NAD+ metabolome . • [2] Martens et al. Randomized nicotinamide-riboside crossover trial . • [3] Grant et al. Metabolome during intravenous NAD+ infusion . • [4] Reyna et al. Retrospective IV NAD+ tolerability pilot . Educational material only. It does not provide dosing or use advice.

References

  1. Human nicotinamide-riboside metabolome study
  2. Randomized nicotinamide-riboside crossover trial
  3. IV NAD+ metabolome pilot
  4. Retrospective IV NAD+ tolerability pilot

Authoritative sources cited for research context. Research use only — not medical advice.

Curious what the research says? Ask me →